Literature DB >> 15946939

AIP4 restricts transforming growth factor-beta signaling through a ubiquitination-independent mechanism.

François Lallemand1, Su Ryeon Seo, Nathalie Ferrand, Marcia Pessah, Sebastien L'Hoste, Georges Rawadi, Sergio Roman-Roman, Jacques Camonis, Azeddine Atfi.   

Abstract

Smad7 functions as an intracellular antagonist in transforming growth factor-beta (TGF-beta) signaling. In addition to interacting stably with the activated TGF-beta type I receptor (TbetaRI) to prevent phosphorylation of the receptor-regulated Smads (Smad2 and Smad3), Smad7 also induces degradation of the activated TbetaRI through association with different E3 ubiquitin ligases. Using the two-hybrid screen, we identified atrophin 1-interacting protein 4 (AIP4) as an E3 ubiquitin ligase that specifically targets Smad7 for ubiquitin-dependent degradation without affecting the turnover of the activated TbetaRI. Surprisingly, we found that despite the ability to degrade Smad7, AIP4 can inhibit TGF-beta signaling, presumably by enhancing the association of Smad7 with the activated TbetaRI. Consistent with this notion, expression of a catalytic mutant of AIP4, which is unable to induce ubiquitination and degradation of Smad7, also stabilizes the TbetaRI.Smad7 complex, resulting in inhibition of TGF-beta signaling. The ability of AIP4 to enhance the inhibitory function of Smad7 independent of its ubiquitin ligase activity reveals a new mechanism by which E3 ubiquitin ligases may function to turn off TGF-beta signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946939     DOI: 10.1074/jbc.M500188200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  ITCH as a potential therapeutic target in human cancers.

Authors:  Qing Yin; Clayton J Wyatt; Tao Han; Keiran S M Smalley; Lixin Wan
Journal:  Semin Cancer Biol       Date:  2020-03-10       Impact factor: 15.707

Review 2.  Multifaceted role of the ubiquitin ligase Itch in immune regulation.

Authors:  K Venuprasad; Minghui Zeng; Scott L Baughan; Ramin Massoumi
Journal:  Immunol Cell Biol       Date:  2015-01-13       Impact factor: 5.126

3.  RNF11 sequestration of the E3 ligase SMURF2 on membranes antagonizes SMAD7 down-regulation of transforming growth factor β signaling.

Authors:  Ryan J Malonis; Wenxiang Fu; Mark J Jelcic; Marae Thompson; Brian S Canter; Mary Tsikitis; Francisco J Esteva; Irma Sánchez
Journal:  J Biol Chem       Date:  2017-03-14       Impact factor: 5.157

Review 4.  Post-translational regulation of TGF-β receptor and Smad signaling.

Authors:  Pinglong Xu; Jianming Liu; Rik Derynck
Journal:  FEBS Lett       Date:  2012-05-19       Impact factor: 4.124

Review 5.  Inhibitory SMADs: potential regulators of ovarian function.

Authors:  Qinglei Li
Journal:  Biol Reprod       Date:  2014-12-30       Impact factor: 4.285

Review 6.  Ubiquitin-dependent regulation of TGFbeta signaling in cancer.

Authors:  Luisa Izzi; Liliana Attisano
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

7.  The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

Authors:  Pierrick G J Fournier; Patricia Juárez; Guanglong Jiang; Gregory A Clines; Maria Niewolna; Hun Soo Kim; Holly W Walton; Xiang Hong Peng; Yunlong Liu; Khalid S Mohammad; Clark D Wells; John M Chirgwin; Theresa A Guise
Journal:  Cancer Cell       Date:  2015-05-14       Impact factor: 31.743

8.  The WW-HECT protein Smurf2 interacts with the Docking Protein NEDD9/HEF1 for Aurora A activation.

Authors:  Finola E Moore; Evan C Osmundson; Jennifer Koblinski; Elena Pugacheva; Erica A Golemis; Dipankar Ray; Hiroaki Kiyokawa
Journal:  Cell Div       Date:  2010-09-08       Impact factor: 5.130

9.  Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55.

Authors:  H Wang; K Song; T L Krebs; J Yang; D Danielpour
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

10.  The multifunctional adaptor protein HIP-55 couples Smad7 to accelerate TGF-β type I receptor degradation.

Authors:  Yang Sun; Zi-Jian Li
Journal:  Acta Pharmacol Sin       Date:  2021-07-30       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.